|Bid||0.0000 x N/A|
|Ask||0.0000 x N/A|
|Day's range||0.0000 - 0.0000|
|Beta (5Y monthly)||0.73|
|PE ratio (TTM)||N/A|
|Earnings date||09 Aug 2023 - 14 Aug 2023|
|Forward dividend & yield||N/A (N/A)|
|1y target est||N/A|
Key Insights Given the large stake in the stock by institutions, Adverum Biotechnologies' stock price might be...
Here is how Adial Pharmaceuticals, Inc. (ADIL) and Adverum Biotechnologies (ADVM) have performed compared to their sector so far this year.
Just because a business does not make any money, does not mean that the stock will go down. For example, biotech and...
Adverum (ADVM) initiates dosing in the phase II LUNA study, currently investigating its lead product candidate ixoberogene soroparvovec for wet age-related macular degeneration.
Generally, when a single insider buys stock, it is usually not a big deal. However, when several insiders are buying...
Adverum (ADVM) completes IND amendment with the FDA for initiating the phase II LUNA study on its gene therapy candidate, ADVM-022, for treating wet-age-related macular degeneration. Stock up.